These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 34561632)

  • 1. EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment.
    Friedlaender A; Subbiah V; Russo A; Banna GL; Malapelle U; Rolfo C; Addeo A
    Nat Rev Clin Oncol; 2022 Jan; 19(1):51-69. PubMed ID: 34561632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC.
    Baraibar I; Mezquita L; Gil-Bazo I; Planchard D
    Crit Rev Oncol Hematol; 2020 Apr; 148():102906. PubMed ID: 32109716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The presence of HER2 exon 20 insertion in patients with central nervous system metastases from non-small lung cancer--a potential application in classification for therapy.
    Nicoś M; Krawczyk P; Mlak R; Sawicki M; Jarosz B; Powrózek T; Milanowski P; Trojanowski T; Milanowski J
    Pneumonol Alergol Pol; 2013; 81(4):294-7. PubMed ID: 23744164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune microenvironment features and efficacy of PD-1/PD-L1 blockade in non-small cell lung cancer patients with EGFR or HER2 exon 20 insertions.
    Chen K; Pan G; Cheng G; Zhang F; Xu Y; Huang Z; Fan Y
    Thorac Cancer; 2021 Jan; 12(2):218-226. PubMed ID: 33210451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions.
    Oxnard GR; Lo PC; Nishino M; Dahlberg SE; Lindeman NI; Butaney M; Jackman DM; Johnson BE; Jänne PA
    J Thorac Oncol; 2013 Feb; 8(2):179-84. PubMed ID: 23328547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer.
    Patil T; Mushtaq R; Marsh S; Azelby C; Pujara M; Davies KD; Aisner DL; Purcell WT; Schenk EL; Pacheco JM; Bunn PA; Camidge DR; Doebele RC
    Clin Lung Cancer; 2020 May; 21(3):e191-e204. PubMed ID: 31859066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TAS2940, a novel brain-penetrable pan-ERBB inhibitor, for tumors with HER2 and EGFR aberrations.
    Oguchi K; Araki H; Tsuji S; Nakamura M; Miura A; Funabashi K; Osada A; Tanaka S; Suzuki T; Kobayashi SS; Mizuarai S
    Cancer Sci; 2023 Feb; 114(2):654-664. PubMed ID: 36282234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence, clinicopathologic characteristics, and molecular associations of EGFR exon 20 insertion mutations in East Asian patients with lung adenocarcinoma.
    Pan Y; Zhang Y; Li Y; Hu H; Wang L; Li H; Wang R; Ye T; Luo X; Zhang Y; Li B; Cai D; Shen L; Sun Y; Chen H
    Ann Surg Oncol; 2014 Dec; 21 Suppl 4():S490-6. PubMed ID: 24419753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of epidermal growth factor receptor and human epidermal growth factor receptor 2 activating mutations in lung adenocarcinoma by high-resolution melting amplicon analysis: correlation with gene copy number, protein expression, and hormone receptor expression.
    Willmore-Payne C; Holden JA; Layfield LJ
    Hum Pathol; 2006 Jun; 37(6):755-63. PubMed ID: 16733218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics.
    Arcila ME; Nafa K; Chaft JE; Rekhtman N; Lau C; Reva BA; Zakowski MF; Kris MG; Ladanyi M
    Mol Cancer Ther; 2013 Feb; 12(2):220-9. PubMed ID: 23371856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer.
    Robichaux JP; Elamin YY; Tan Z; Carter BW; Zhang S; Liu S; Li S; Chen T; Poteete A; Estrada-Bernal A; Le AT; Truini A; Nilsson MB; Sun H; Roarty E; Goldberg SB; Brahmer JR; Altan M; Lu C; Papadimitrakopoulou V; Politi K; Doebele RC; Wong KK; Heymach JV
    Nat Med; 2018 May; 24(5):638-646. PubMed ID: 29686424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of tarloxotinib-E in cells with EGFR exon-20 insertion mutations and mechanisms of acquired resistance.
    Nishino M; Suda K; Koga T; Ohara S; Fujino T; Soh J; Tirunagaru V; Vellanki A; Doebele RC; Mitsudomi T
    Thorac Cancer; 2021 May; 12(10):1511-1516. PubMed ID: 33710795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of Recurrent Insertions and Deletions in Exon 18 and 19 of Human Epidermal Growth Factor Receptor 2 as Potential Drivers in Non-Small-Cell Lung Cancer and Other Cancer Types.
    Yin Y; Song L; Shi D; Liu B; Li X; Yang M; Liu B; Wang D; Qin J
    JCO Precis Oncol; 2022 Feb; 6():e2100325. PubMed ID: 35171661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human epidermal growth factor receptor 2-positive metastatic breast cancer with novel epidermal growth factor receptor -ZNF880 fusion and epidermal growth factor receptor E114K mutations effectively treated with pyrotinib: A case report.
    Yue L; Wentao L; Xin Z; Jingjing H; Xiaoyan Z; Na F; Tonghui M; Dalin L
    Medicine (Baltimore); 2020 Dec; 99(51):e23406. PubMed ID: 33371069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Somatic mutations of the HER2 in metastatic breast cancer.
    Fang Y; Jiang Y; Wang X; Yang X; Gao Y; Wang J
    Tumour Biol; 2014 Dec; 35(12):11851-4. PubMed ID: 25326805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.
    Kosaka T; Tanizaki J; Paranal RM; Endoh H; Lydon C; Capelletti M; Repellin CE; Choi J; Ogino A; Calles A; Ercan D; Redig AJ; Bahcall M; Oxnard GR; Eck MJ; Jänne PA
    Cancer Res; 2017 May; 77(10):2712-2721. PubMed ID: 28363995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extensive functional evaluation of exon 20 insertion mutations of EGFR.
    Hirose T; Ikegami M; Endo M; Matsumoto Y; Nakashima Y; Mano H; Kohsaka S
    Lung Cancer; 2021 Feb; 152():135-142. PubMed ID: 33395611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling.
    Wilding B; Scharn D; Böse D; Baum A; Santoro V; Chetta P; Schnitzer R; Botesteanu DA; Reiser C; Kornigg S; Knesl P; Hörmann A; Köferle A; Corcokovic M; Lieb S; Scholz G; Bruchhaus J; Spina M; Balla J; Peric-Simov B; Zimmer J; Mitzner S; Fett TN; Beran A; Lamarre L; Gerstberger T; Gerlach D; Bauer M; Bergner A; Schlattl A; Bader G; Treu M; Engelhardt H; Zahn S; Fuchs JE; Zuber J; Ettmayer P; Pearson M; Petronczki M; Kraut N; McConnell DB; Solca F; Neumüller RA
    Nat Cancer; 2022 Jul; 3(7):821-836. PubMed ID: 35883003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy.
    Teng YH; Tan WJ; Thike AA; Cheok PY; Tse GM; Wong NS; Yip GW; Bay BH; Tan PH
    Breast Cancer Res; 2011 Apr; 13(2):R35. PubMed ID: 21457545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.